BioCentury
ARTICLE | Company News

Acceleron, Celgene amend sotatercept deal for pulmonary hypertension

September 22, 2017 8:31 PM UTC

Acceleron Pharma Inc. (NASDAQ:XLRN) gained worldwide rights to develop and commercialize sotatercept to treat pulmonary hypertension, amending a deal with partner Celgene Corp.(NASDAQ:CELG). Acceleron expects to begin a Phase II trial of sotatercept to treat pulmonary arterial hypertension (PAH) in 1H18.

In 2008, Acceleron and Celgene partnered to co-develop and commercialize Acceleron's sotatercept for all indications, with an initial focus on cancer, including breast and ovarian cancers, and cancer-related bone loss. At the time, Acceleron received $50 million up front, including a $5 million equity investment by Celgene, and was eligible for up to $510 million in milestones, plus tiered royalties (see BioCentury, Feb. 25, 2008)...